CJC with DAC 5mg

CJC with DAC 5mg — Long-Acting GHRH Analog Research Peptide

CJC with DAC is a modified growth hormone-releasing hormone (GHRH) analog featuring a Drug Affinity Complex (DAC) modification that dramatically extends its functional half-life. The DAC technology incorporates a maleimide group that forms a covalent bond with serum albumin, transforming a typically short-lived GHRH analog into a research peptide with multi-day pharmacokinetics. This unique profile has made CJC with DAC an important reference compound in extended-duration growth hormone axis research within the growth hormone peptides research category.

DAC Technology and Extended Half-Life

The DAC modification on CJC with DAC represents a sophisticated approach to extending peptide half-life that overcomes the rapid clearance typical of small peptides. By covalently binding to serum albumin via a thiol-reactive maleimide group, the peptide effectively hijacks albumin’s long half-life and large molecular size, dramatically reducing renal clearance and proteolytic degradation. Research has documented functional half-lives extending several days, enabling experimental designs not possible with conventional GHRH analogs.

GHRH Receptor Pharmacology

CJC with DAC binds to GHRH receptors expressed on pituitary somatotrophs, stimulating both synthesis and pulsatile release of endogenous growth hormone. Importantly, despite its extended half-life in circulation, the pulsatile pattern of growth hormone release appears to be preserved in laboratory animals, with peaks superimposed on a baseline of sustained somatotroph stimulation generating a hybrid pharmacological signature.

Growth Hormone and IGF-1 Research

Studies in laboratory animals have documented that CJC with DAC produces sustained elevations in growth hormone pulse amplitude and consequent increases in IGF-1 levels. The duration of effect from a single research dose extends across multiple days, contrasting with the hours-long duration of shorter-acting GHRH analogs. This pharmacokinetic profile makes CJC with DAC particularly useful for chronic somatotropic axis studies.

Metabolic and Body Composition Studies

Research has examined CJC with DAC’s effects on metabolic parameters and body composition in animal models. Studies have documented changes in adiposity, lean mass, and metabolic markers consistent with sustained growth hormone exposure. The extended half-life enables investigation of chronic effects in dosing regimens that would be impractical with shorter-acting compounds.

Bone, Connective Tissue, and Aging Research

Additional research has examined CJC with DAC’s effects on bone metabolism, connective tissue, and biomarkers associated with aging. The peptide’s sustained signaling profile supports investigation of long-term anabolic effects on collagen turnover, mineral handling, and tissue remodeling biology in animal models.

Comparison With Related GH Peptides

CJC with DAC is frequently compared against shorter-acting GHRH analogs such as Sermorelin and Tesamorelin, as well as combined blends like CJC 1295 + Ipamorelin. Parallel investigations help characterize how extended-duration GHRH stimulation compares against more pulsatile compounds.

Quality, Storage, and Compliance

Each vial of CJC with DAC 5mg is manufactured to 99%+ HPLC-verified purity and supplied as a sterile lyophilized powder. Store unreconstituted vials at -20°C; reconstituted material should be refrigerated at 2–8°C. This CJC with DAC product is sold strictly for in-vitro laboratory research only — not for human consumption, diagnostic use, or any clinical application. Buyers must comply with all applicable provincial and federal regulations.